NDO-LID Rapid Test (OrangeLife and IDRI)
An immunochromatographic assay combining the natural disaccharide octyl carbohydrate epitope with the LID-1 fusion protein, capturing both IgM and IgG responses in a single device.
- Technology
- Serology (Antibody) · Lateral flow
- What it measures
- IgM anti-PGL-I (NDO) and IgG anti-LID-1 fusion antigen
- Developer
- OrangeLife (Rio de Janeiro, Brazil) with IDRI, now AAHI (Seattle, WA, USA)
- Specimen
- Capillary blood
- Development status
- Commercial RUO with clinical validation
- Regulatory status
- None / RUO
- Intended use
- Point-of-care serological detection and support for operational classification
- Main limitation
- Reduced sensitivity in paucibacillary disease persists despite the dual-antigen format.
- Availability
- No longer available. OrangeLife's online shop has been out of service since 2025, and the test is not listed on the FIND DxConnect Marketplace (checked 18 September 2026). Brazil's public health system has used the Bioclin Fast ML Flow test since 2023.
- Linked publications
- 10
- Collaborating institutions
- Federal University of Goiás (Goiânia, Brazil)
- TPP-1, confirming leprosy
- 60.0 of 100, partial alignment
- TPP-2, infection in contacts
- 64.0 of 100, partial alignment
Open this test in the landscapeAll 37 tests · Home